Comparative analysis of sorafenib and lenvatinib on HepG2 cells and human umbilical vein endothelial cells: Involvement of transforming growth factor-β signaling in their molecular effects.
Ting WangYasuhiro TakikawaKazuyuki SuzukiHidekatsu KurodaKeisuke KakisakaToshimi ChibaPublished in: Hepatology research : the official journal of the Japan Society of Hepatology (2024)
Our findings indicate that both sorafenib and lenvatinib possess anticancer abilities by inducing the cytotoxicity of hepatocellular carcinoma cells. Furthermore, they show opposing effects on TGF-β-induced cell invasion and angiogenesis, thereby enhancing the understanding of the multifaceted functions of molecular targeted drugs in treating hepatocellular carcinoma.